Drug intelligence / Profile preview

DiKine

Development stage: Preclinical
Lead developer: Evive Biotech
Modality: Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
Administration: Subcutaneous

Overview

DiKine is a preclinical recombinant fusion protein candidate being developed by Evive Biotech for the treatment of diabetes and obesity. The drug is engineered using the proprietary DiKine™ bimolecular structure platform, which is designed to create long-acting therapeutic proteins by fusing them to an Fc homodimer, thereby improving stability and extending half-life. While the specific biological targets for this metabolic program remain undisclosed, the platform is typically utilized to optimize the delivery and efficacy of cytokines or growth factors. It is currently in the preclinical stage of development.

Other names: DiKine platform-based recombinant fusion protein

Beyond the preview

Go deeper on DiKine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DiKine.

Explore the full profile